Merck preps PhIII program for HIV therapy; Bill Gates tops up annual malaria R&D commitment to $200M;

@FierceBiotech: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies. News | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers beefs up fibrosis pipeline with $444M option deal. Report | Follow @JohnCFierce

@DamianFierce: $BMY gets into IPF with Galecto (and Magnus Persson, its fantastically named chairman) in a deal worth up to $444M. Release | Follow @DamianFierce

@EmilyMFierce: The planet's deadliest infectious diseases, by country. More via Salon | Follow @EmilyMFierce

> Merck ($MRK) says that a Phase IIb study of its next-gen HIV therapy doravirine (or MK-1439) demonstrated an improved safety profile over Sustiva, an HIV drug it developed in its lab and licensed out to Bristol-Myers Squibb ($BMY). Investigators say they're ready to barrel into late-stage studies before the end of this year. Sustiva loses U.S. patent protection at the end of 2017. Release

> Determined to end malaria in his lifetime, billionaire Bill Gates says his foundation will increase its annual budget on malaria research to $200 million a year, a 30% increase. Report

Medical Device News

@FierceMedDev: ICYMI: Diagnostic companies homing on on rapid mobile tests to quell Ebola outbreak. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: UPDATED: Medtronic discloses new corporate structure upon Covidien deal close. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific set to face first federal trials over transvaginal mesh products. Reuters article | Follow @EmilyWFierce

> With new fund, Rock Health to invest more money in fewer companies. Story

> Boston Scientific faces first two federal trials for transvaginal mesh devices. Article

CRO News

> PRA raises the stakes, eyeing $400M in a blockbuster IPO. More

> CRO Paragon raises $13M to expand its footprint. Story

> LabCorp is buying Covance for $5.6B to cut in on the CRO boom. News

> Timely deals boost Charles River's balance sheet. Story

> Quintiles posts another $1B quarter and dials up its expectations. Report

Biotech IT News

> Venter makes new hires at Synthetic Genomics and Human Longevity. Item

> Cleveland Clinic teams with IBM to use Watson in genomics cancer research. Report

> Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs. More

> Novo Nordisk pushes back date of IT IPO decision to 2015. Story

> Boehringer picks IDBS system in consolidation of ELN. Article

Animal Health News

> IDEXX follows positive earnings with acquisition of Animana. Item

> Advaxis sees encouraging results for immuno-oncology treatment in dogs with bone cancer. Report

> Analysts to Heska: Why has strong performance been overlooked? Article

> Jaguar Animal Health trims IPO target number by 26%. More

> Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes. Story

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.